Agenus reports 48% estimated three-year survival with BOT+BAL
Agenus said BOT+BAL showed a 48% estimated three-year survival in recurrent ovarian cancer, presented at IGCS 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Agenus reports 48% three-year survival with BOT+BAL in ovarian cancer
Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial, evaluating botensilimab (BOT) in combination with balstilimab (BAL). The study showed an estimated three-year survival rate of 48% in recurrent ovarian cancer.